Powder: -20°C for 3 years | In solvent: -80°C for 1 year
NPS2390 is a first generation quinoxaline derivative that acts as a noncompetitive antagonist of mGluR1 and mGluR5 (IC50 of 5.2 and 82 nM, respectively)
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
2 mg | In stock | $ 37.00 | |
5 mg | In stock | $ 59.00 | |
10 mg | In stock | $ 97.00 | |
25 mg | In stock | $ 189.00 | |
50 mg | In stock | $ 328.00 | |
100 mg | In stock | $ 538.00 | |
200 mg | In stock | $ 741.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 86.00 |
Description | NPS2390 is a first generation quinoxaline derivative that acts as a noncompetitive antagonist of mGluR1 and mGluR5 (IC50 of 5.2 and 82 nM, respectively) |
Targets&IC50 | mGluR5:82 nM, mGluR1:5.2nM |
In vitro | Treatment of NPS2390 was conducive to inhibit the proliferation and reverse phenotypic modulation of PASMCs by regulating autophagy levels. |
Molecular Weight | 307.39 |
Formula | C19H21N3O |
CAS No. | 226878-01-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 3.07 mg/mL (10 mM), Sonification is recommended
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
NPS2390 226878-01-9 Neuroscience GluR Inhibitor Calcium-sensing receptor NPS 2390 mGluR inhibit Metabotropic glutamate receptors CaSR NPS-2390 inhibitor